In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene

Joaquim Ruiz, Francesc Marco, Josep M. Sierra, Lorenzo Aguilar, Elena Garcia-Mendez, Josep Mensa, M. Teresa Jiménez De Anta, Jordi Vila

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

10 Citas (Scopus)

Resumen

The MIC of gemifloxacin and five other quinolones was tested against 31 clinical isolates of Neisseria gonorrhoeae; strains were analyzed for the presence of mutations in both the gyrA and parC genes. Only seven strains were resistant to nalidixic acid due to a mutation in the gyrA gene but not in the parC gene, with six and two considered intermediate to ciprofloxacin and levofloxacin, respectively. The activity of gemifloxacin was similar to that of trovafloxacin and moxifloxacin, but was more active than nalidixic acid, ciprofloxacin or levofloxacin against the gyrA mutant strains. Gemifloxacin is a valid therapeutic alternative to treat infections with N. gonorrhoeae, retaining its activity against strains already presenting a mutation in gyrA.

Idioma originalInglés
Páginas (desde-hasta)73-76
Número de páginas4
PublicaciónInternational Journal of Antimicrobial Agents
Volumen22
N.º1
DOI
EstadoPublicada - 1 jul. 2003

Huella

Profundice en los temas de investigación de 'In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene'. En conjunto forman una huella única.

Citar esto